<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00242203</url>
  </required_header>
  <id_info>
    <org_study_id>02-0788 / 201104272</org_study_id>
    <nct_id>NCT00242203</nct_id>
  </id_info>
  <brief_title>Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer</brief_title>
  <official_title>Impact of Neoadjuvant Chemotherapy With or Without Zometa on Occult Micrometastases and Bone Density in Women With Locally Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the impact of Zometa on clearance of bone marrow
      micrometastases; the protective effect on chemotherapy-induced loss of bone mineral density;
      and quality of life in women undergoing treatment for locally advanced breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the impact of Zometa (zoledronic acid) on the clearance of bone marrow micrometastases</measure>
    <time_frame>Prior to therapy initiation, after completion of neoadjuvant chemotherapy, and 12-15 months from registration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the protective effect of Zometa (zoledronic acid) on chemotherapy-induced loss of bone mineral density</measure>
    <time_frame>Prior to therapy initiation and 12-15 months from registration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of Zometa (zoledronic acid) on time and site of relapse</measure>
    <time_frame>5 years from registration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of treatment on quality of life in women undergoing treatment for LABC.</measure>
    <time_frame>Baseline and 12-15 months from registration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Zometa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zometa 4 mg IV every 3 weeks for a total of 17 doses. The first treatment will be given at the time of the first chemotherapy treatment and will continue for approximately 1 year.
Neoadjuvant therapy
Epirubicin 75 mg/m2 IV every 21 days for 4 cycles prior to surgery
Docetaxel 75 mg/m2 IV every 21 days for 4 cycles prior to surgery
Surgery - modified radical mastectomy or breast conserving surgery with axillary lymph node dissection
Adjuvant therapy
Epirubicin 75 mg/m2 IV every 21 days for 2 cycles
Docetaxel 75 mg/m2 IV every 21 days for 2 cycles
All patients who are found to be Her-2 overexpressing by 3+ by ICH for FSH will receive trastuzumab 6 mg/kg IV every 3 weeks for 1 year post surgery
Radiation therapy - 50-60 Gy in 1.8-2.0 Gy daily fractions to the breast or chest wall. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Zometa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant therapy
Epirubicin 75 mg/m2 IV every 21 days for 4 cycles prior to surgery
Docetaxel 75 mg/m2 IV every 21 days for 4 cycles prior to surgery
Surgery - modified radical mastectomy or breast conserving surgery with axillary lymph node dissection
Adjuvant therapy
Epirubicin 75 mg/m2 IV every 21 days for 2 cycles
Docetaxel 75 mg/m2 IV every 21 days for 2 cycles
All patients who are found to be Her-2 overexpressing by 3+ by ICH for FSH will receive trastuzumab 6 mg/kg IV every 3 weeks for 1 year post surgery
Radiation therapy - 50-60 Gy in 1.8-2.0 Gy daily fractions to the breast or chest wall. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zometa</intervention_name>
    <arm_group_label>Zometa</arm_group_label>
    <other_name>Zoledronic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <arm_group_label>Zometa</arm_group_label>
    <arm_group_label>No Zometa</arm_group_label>
    <other_name>Ellence</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Zometa</arm_group_label>
    <arm_group_label>No Zometa</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>ONLY for patients that are Her-2 overexpressing by 3+ by ICH for FSH</description>
    <arm_group_label>Zometa</arm_group_label>
    <arm_group_label>No Zometa</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External beam radiation</intervention_name>
    <arm_group_label>Zometa</arm_group_label>
    <arm_group_label>No Zometa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection</intervention_name>
    <arm_group_label>Zometa</arm_group_label>
    <arm_group_label>No Zometa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed primary invasive ductal or invasive lobular breast adenocarcinoma

          -  Tumor classified as clinically large T2 (2-5 cm), T3, T4 or any T with N1, N2

          -  Prior malignancies: limited to curatively treated basal or squamous carcinoma of the
             skin or history of previous malignancies, treated and now &gt; 5 years disease free

          -  &gt;= 18 years of age

          -  Normal left ventricular function by echocardiogram or radioventriculogram

          -  Karnofsky Performance &gt;= 70

        Exclusion Criteria:

          -  No evidence of distant metastasis present by CT, Bone scan, or physical exam

          -  If the bone scan or CT scans demonstrate indeterminate lesions, the nature of these
             lesions may be further clarified by additional testing such as PET or MRI

          -  No current treatment with Zometa or other bisphosphonates

          -  No serious functional disorders of the liver or kidneys:

          -  Serum Creatinine &lt;=2

          -  ALT/AST/ALK Phos &lt;= 1.5 x upper limit of institutional normal.

          -  Bili &lt;= 1.5 x upper limit of institutional normal.

          -  Currently not pregnant
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca Aft, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <reference>
    <citation>Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993 Jun;94(6):646-50. Review.</citation>
    <PMID>8506892</PMID>
  </reference>
  <reference>
    <citation>Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med. 1997 Aug 18;103(2A):12S-17S; discussion 17S-19S. Review.</citation>
    <PMID>9302893</PMID>
  </reference>
  <reference>
    <citation>Schürch MA, Rizzoli R, Mermillod B, Vasey H, Michel JP, Bonjour JP. A prospective study on socioeconomic aspects of fracture of the proximal femur. J Bone Miner Res. 1996 Dec;11(12):1935-42.</citation>
    <PMID>8970896</PMID>
  </reference>
  <reference>
    <citation>Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000 Apr;18(7):1570-93. Review.</citation>
    <PMID>10735906</PMID>
  </reference>
  <reference>
    <citation>Cann CE, Martin MC, Genant HK, Jaffe RB. Decreased spinal mineral content in amenorrheic women. JAMA. 1984 Feb 3;251(5):626-9.</citation>
    <PMID>6690836</PMID>
  </reference>
  <reference>
    <citation>Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol. 2001 Jul 15;19(14):3306-11.</citation>
    <PMID>11454877</PMID>
  </reference>
  <reference>
    <citation>Young DM, Fioravanti JL, Olson HM, Prieur DJ. Chemical and morphologic alterations of rabbit bone induced by adriamycin. Calcif Tissue Res. 1975 Jul 4;18(1):47-63.</citation>
    <PMID>1148891</PMID>
  </reference>
  <reference>
    <citation>Glackin CA, Murray EJ, Murray SS. Doxorubicin inhibits differentiation and enhances expression of the helix-loop-helix genes Id and mTwi in mouse osteoblastic cells. Biochem Int. 1992 Oct;28(1):67-75.</citation>
    <PMID>1280141</PMID>
  </reference>
  <reference>
    <citation>Reid IR. Glucocorticoid osteoporosis--mechanisms and management. Eur J Endocrinol. 1997 Sep;137(3):209-17. Review.</citation>
    <PMID>9330580</PMID>
  </reference>
  <reference>
    <citation>Van Staa T, Abenhaim L, Cooper C: Use of cyclic etidronate and prevention of fractures. Bone 20:103s (abstract), 1997</citation>
  </reference>
  <reference>
    <citation>Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996 Dec 7;348(9041):1535-41.</citation>
    <PMID>8950879</PMID>
  </reference>
  <reference>
    <citation>McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001 Feb 1;344(5):333-40.</citation>
    <PMID>11172164</PMID>
  </reference>
  <reference>
    <citation>Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002 Feb 28;346(9):653-61.</citation>
    <PMID>11870242</PMID>
  </reference>
  <reference>
    <citation>Saarto T, Blomqvist C, Välimäki M, Mäkelä P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol. 1997 Apr;15(4):1341-7.</citation>
    <PMID>9193325</PMID>
  </reference>
  <reference>
    <citation>Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol. 1997 Mar;15(3):955-62.</citation>
    <PMID>9060533</PMID>
  </reference>
  <reference>
    <citation>Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000 Apr;82(8):1459-68.</citation>
    <PMID>10780527</PMID>
  </reference>
  <reference>
    <citation>Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest. 1996 Oct 1;98(7):1544-9.</citation>
    <PMID>8833902</PMID>
  </reference>
  <reference>
    <citation>Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ, Gillespie MT. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 1999 Oct;140(10):4451-8.</citation>
    <PMID>10499498</PMID>
  </reference>
  <reference>
    <citation>Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem. 1986 Sep 25;261(27):12665-74.</citation>
    <PMID>3745206</PMID>
  </reference>
  <reference>
    <citation>Pfeilschifter J, Mundy GR. Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci U S A. 1987 Apr;84(7):2024-8.</citation>
    <PMID>3494250</PMID>
  </reference>
  <reference>
    <citation>Yin J, Chirgwin J, Taylor S: Dominant negative blockade of the transforming growth factor beta type II receptor decreases breast cancer mediated osteolysis. Journal of Bone and Mineral Research 11:180, 1996</citation>
  </reference>
  <reference>
    <citation>Mundy GR, Yoneda T. Bisphosphonates as anticancer drugs. N Engl J Med. 1998 Aug 6;339(6):398-400.</citation>
    <PMID>9691109</PMID>
  </reference>
  <reference>
    <citation>Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 1995 Aug 15;55(16):3551-7.</citation>
    <PMID>7627963</PMID>
  </reference>
  <reference>
    <citation>Hall DG, Stoica G. Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system. J Bone Miner Res. 1994 Feb;9(2):221-30.</citation>
    <PMID>8140935</PMID>
  </reference>
  <reference>
    <citation>Yoneda T, Sasaki A, Dunstan C, Williams PJ, Bauss F, De Clerck YA, Mundy GR. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest. 1997 May 15;99(10):2509-17.</citation>
    <PMID>9153295</PMID>
  </reference>
  <reference>
    <citation>Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer. 2000 Jun 15;88(12 Suppl):2979-88. Review.</citation>
    <PMID>10898341</PMID>
  </reference>
  <reference>
    <citation>Elomaa I, Blomqvist C, Porkka L, Lamberg-Allardt C, Borgström GH. Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone. 1987;8 Suppl 1:S53-6.</citation>
    <PMID>2961355</PMID>
  </reference>
  <reference>
    <citation>Kanis JA, Powles T, Paterson AH, McCloskey EV, Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone. 1996 Dec;19(6):663-7.</citation>
    <PMID>8968035</PMID>
  </reference>
  <reference>
    <citation>Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, Bonneterre J, Francini G, Ford JM. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol. 1996 Sep;14(9):2552-9.</citation>
    <PMID>8823335</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2005</study_first_submitted>
  <study_first_submitted_qc>October 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2005</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Neoadjuvant</keyword>
  <keyword>Micrometastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Zoledronic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

